Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.

Autor: Godwin CD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA., Bates OM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Jean SR; Eutropics Pharmaceuticals, Inc, Cambridge, MA, USA., Laszlo GS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Garling EE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Beddoe ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Cardone MH; Eutropics Pharmaceuticals, Inc, Cambridge, MA, USA., Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (12), pp. 2990-2994. Date of Electronic Publication: 2020 Jul 04.
DOI: 10.1080/10428194.2020.1786553
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje